Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
LIRA and SEMA gained approval from the Food and Drug Administration and the European Medicines Agency for weight loss in obese individuals or people who are overweight with BMI 27 kg/m 2 and have experienced at least one weight-associated comorbid condition (such as prediabetes, hypertension, dyslipidaemia, and OSA) combined with lifestyle modifications [63]
Improved glycemic control and reduced blood sugar levels are achieved without increasing the risk of hypoglycemia low blood sugar a common concern with other diabetes medications
Nausea is one of the most frequently reported side effects, affecting approximately 50% of patients taking GLP-1 medications, whilst vomiting occurs in about 15-25% of patients
AstraZenecas camizestrant, with its innovative trial design, reduced this risk by 56%
